Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; New York State Psychiatric Institute, New York, NY, USA.
Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; New York State Psychiatric Institute, New York, NY, USA.
Clin Ther. 2021 Jan;43(1):85-94. doi: 10.1016/j.clinthera.2020.11.006. Epub 2020 Dec 5.
Anorexia nervosa (AN) is a devastating psychiatric disorder characterized by extreme restriction of food intake and low body weight, both associated with significant medical and psychological morbidity. The clinical severity of AN has prompted the consideration and study of behavioral and pharmacological treatments in efforts to establish empirically based methods to reduce the burden of the disorder. Among adolescents, family-based treatment is considered a first-line behavioral treatment. Research continues to explore the efficacy of family-based treatment and predictors of treatment response to further improve outcomes. Several behavioral treatments for adults also exist, including cognitive-behavioral therapy, exposure and response prevention, third-wave acceptance-based treatments, and supportive psychotherapy, all of which help to improve symptoms and promote modest weight gain. Despite this, no one treatment is considered superior, and all existing behavioral approaches leave a proportion of adults symptomatic or at a high risk of relapse. As such, among adults, there is continued need for development of novel, mechanism-based approaches to better target the core symptoms of AN. Although antidepressants impart little benefit on weight or symptoms, the second-generation antipsychotic olanzapine has shown ability to promote modest weight gain in outpatients with AN. Most recently, the field's evolving conceptualization of AN as a biologically based disorder coupled with technological advancements has led to consideration of varying neuromodulation strategies as a potential therapeutic approach that remains under investigation.
神经性厌食症(AN)是一种严重的精神疾病,其特征为极度限制食物摄入和体重过低,两者都与显著的医疗和心理病态相关。AN 的临床严重程度促使人们考虑和研究行为和药物治疗,以努力建立基于经验的方法来减轻这种疾病的负担。在青少年中,家庭为基础的治疗被认为是一线行为治疗。研究继续探索家庭为基础的治疗的疗效和治疗反应的预测因素,以进一步改善结果。也有几种针对成人的行为治疗方法,包括认知行为疗法、暴露和反应预防、第三波基于接受的治疗和支持性心理治疗,所有这些方法都有助于改善症状和促进适度的体重增加。尽管如此,没有一种治疗方法被认为是优越的,所有现有的行为方法都会让一部分成年人出现症状或有很高的复发风险。因此,对于成年人来说,仍然需要开发新的、基于机制的方法来更好地针对 AN 的核心症状。尽管抗抑郁药对体重或症状几乎没有益处,但第二代抗精神病药奥氮平已显示出能够促进门诊 AN 患者适度的体重增加。最近,该领域对 AN 作为一种基于生物学的疾病的概念化的发展以及技术进步,促使人们考虑各种神经调节策略作为一种潜在的治疗方法,这仍在研究中。